

Abstract

Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, *Escherichia coli, Streptococcus pneumoniae and Staphylococcus aureus* are among the major bacterial causative agents of lower respiratory tract infections (LRTIs), causing substantial morbidity and mortality globally. The rapid increase of antimicrobial resistance (AMR) in these pathogens poses significant challenges for effective antibiotic therapy of LRTIs. In low-resourced settings, the diagnostics of LRTIs relies heavily on microbiological culture and patients are often treated with empirical antibiotics while awaiting several days for culture results. Rapid detection of LRTIs pathogens and AMR genes could prompt early antibiotic switching and inform antibiotic treatment duration. In this study, we developed multiplex quantitative real-time PCRs using EvaGreen dye and melting curve analysis (MCA) to rapidly identify the six major LRTIs pathogens and their AMR genes directly from the tracheal aspirate and sputum samples. The accuracy of RT-PCRs was assessed by comparing its performance against the gold standard, conventional culture method on 50 tracheal aspirate and sputum specimens. Our RT-PCR assays had 100% sensitivity for *K. pneumoniae*, *A. baumannii*, *P. aeruginosa*, *E. coli* and 63.6% for *S. aureus* and the specificity ranked from 87.5% to 97.6%. The kappa correlation values of all pathogens between the two methods varied from 0.63 to 0.95. The limit of detection (LOD) of target bacteria in multiplex RT-PCRs was 1600 CFU/mL. Compared to the culture results, PCR assays exhibited higher sensitivity in detecting mixed infections and *S. pneumoniae*. Our findings also demonstrated a high level of concordance between the detection of AMR gene and AMR phenotype in single infections. We conclude that our multiplex quantitative RT-PCRs with fluorescence MCA is simple but sensitive and specific in detecting six major drug resistant bacterial pathogens of LRTIs and should be further evaluated for clinical utility.

-
-
-
-
-

Introduction

- Lower respiratory tract infections (LRTIs) are the leading infectious cause of morbidity and
- mortality globally. It is estimated that 336 million episodes of LRTIs occurred in 2016, resulting
- 63 in nearly 2.4 million deaths of all ages and 652,000 deaths in children less than 5 years 1 .
- Although viruses such as influenza virus and respiratory syncytial virus (RSV) are responsible
- for a largest proportion of LRTIs, most deaths are caused by bacterial agents, including
- *Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Pseudomonas*
- *aeruginosa, Klebsiella pneumoniae, Escherichia coli* and *Acinetobacter baumannii* 2–4 .
- In recent years, the worldwide increase of antimicrobial resistance (ARM) in respiratory bacterial
- 69 pathogens threatens the effectiveness of antibiotic treatment . Multidrug-resistant (MDR) Gram-
- negative pathogens are more frequently identified from patients with LRTIs, especially in ICUs,
- 71 leading to increased risks of poor outcome, prolonged hospital stay, and mortality . Early and
- rapid detection of LRTIs pathogens and its AMR phenotype is key to inform appropriate
- antibiotic therapy and reduce risks of severe complications and mortality among LRTI patients
- $74 \frac{3,7,8}{.}$
- Currently, a variety of traditional diagnostic methods are used to detect respiratory pathogens,
- including microscopic examination, bacterial culture, and antigen detection 9 . These methods
- often require a collection of various specimens with low sensitivity and long turnaround time 9 .
- Recently, several molecular PCR-based assays have been developed for the diagnostics of
- respiratory pathogens. Luminex assays and TaqMan array cards can detect many viruses and
- 80 bacteria simultaneously $10,11$. The BioFire FilmArray Pneumonia Panel and Pneumonia Plus
- Panel can detect 18 bacteria (11 Gram negative, 4 Gram positive and 3 atypical)**,** 7 AMR
- 82 markers, and 9 viruses that cause pneumonia . However, the BioFire FilmArray assays are
- expensive and may not be adopted for routine diagnostics, particularly in low- and middle-
- 84 income (LMIC) settings ¹³.

Alternatively, multiplex real-time PCR with either fluorescent probe or fluorescent dye targeting key locally relevant bacterial-AMR gene combinations can provide a pragmatic and inexpensive diagnostic method for clinical utility. Compared to probe-based assay, dye-based assay with melting curve analysis (MCA) is less expensive and can detect more targets. The most commonly and successfully used fluorescent dye for multiplex real-time PCR is SYBR Green. However, recently, EvaGreen (EG) dye, a third-generation, new saturating fluorescent dye are proved to be better than SYBR Green due to EG dye can be used at higher concentrations

- 92 without inhibiting PCR and shows equal binding affinity for GC-rich and AT-rich regions 14 . EG-
- based multiplex real-time PCR with melting curve analysis has been developed for the detection
- 94 of multiple bacterial pathogens of respiratory infections $15,16$.
- Here, our study aimed to develop and validate multiplex real-time PCR with EvaGreen MCA
- assays (EG-mPCR assays) to detect six bacteria (4 Gram negative and 2 Gram positive) and
- fourteen AMR genes directly from respiratory specimens.

Materials and methods

Bacteria strains

- To develop and validate our EG-mPCR assays, ATCC strains, clinical strains and off-target
- controls (*Acinetobacter lwoffii, Staphylococcus epidermidis, Shigella sonnei, Salmonella typhi,*
- *Campylobacter jejuni*) were utilized. Standard strains of *E. coli* (ATCC25922), *K. pneumoniae*
- (ATCC700603), *S. pneumoniae* (ATCC49619), *S. aureus* (ATCC25923), *P. aeruginosa*
- (ATCC27853) were purchased from the American Type Culture Collection (ATCC, Manassas,
- VA, USA) and subsequently cultured in Luria-Bertani (LB) agar or nutrient agar (NA). Further,
- eight clinical strains carrying the target AMR genes were used as positive controls for AMR
- gene detection assays.

Clinical samples preparation

- Tracheal aspirate (TA) or sputum samples were collected from patients admitted to Hospital of
- Tropical Diseases in HCMC and sent to the Microbiology Department at Hospital for Tropical
- Diseases for routine microbiological diagnostics. Residual samples were transferred to the
- Molecular Laboratory at Oxford University Clinical Research Unit (OUCRU) for the evaluation of
- 113 the EG-mPCR assays.
-

Microbiological Culture

- The TA and the sputum samples were collected into a sterile container, followed by Gram
- staining and examination under direct microscopy. The samples having <10 epithelial cells and
- >25 leukocytes in each area upon 100x magnification were considered good quality for bacterial
- culture and were included in our study. Samples passing quality checking were liquefied with
- Sputasol liquid (Oxoid, USA) with ratio 1:1 and diluted with MRD broth (maximum recovery

- 121 diluent) with ratio 1:9 before microbiological testing. Subsequently, 1μl of suspension were
- 122 inoculated into blood agar, Macconkey agar and chocolate agar media (Oxoid, USA), and
- 123 incubated for 24-48 hours at 35-37°C or at 35-37°C with ~5% CO₂. Bacterial identification and
- 124 antimicrobial susceptibility testing (AST) was performed using Vitek2 automatic identification
- 125 and AST system (Biomérieux, France). In TA culture, sample with bacterial growth ≥ 10⁵
- 126 CFU/mL was considered positive following the local guidelines for microbiological diagnostics.

127 **Extraction of nucleic acids**

- 128 DNA extraction from bacterial isolates was performed using the Wizard Genomic DNA
- 129 Extraction Kit (Promega, Fitchburg, USA) according to the manufacturer's instructions. The
- 130 quality and concentration of the DNA was assessed using a Nano-drop spectrophotometer prior
- 131 to PCR amplification.
- 132 For TA/sputum samples, an aliquot of 200µl was homogenized with 4 times the volume of 0.1%
- 133 dithiothreitol (DTT) for 15 minutes at room temperature and centrifuged at 8000 rpm for 10
- 134 minutes. Subsequently, supernatant was discarded and pellet was resuspended with 200µl
- 135 PBS. Next, 25μl of 10X buffer (200mM Tris-HCl, 0.2μl of Benzonase (Sigma) and 24.8μl of
- 136 sterilized water) were added, followed by 2-hour incubation at 37° C. The mixture was
- 137 centrifuged at 8000 rpm for 10 minutes and the pellet was subsequently resuspended in a
- 138 mixture of 4μl EDTA, 120μl NaCl and 76μl H₂O. Centrifugation was performed again at 8000
- 139 rpm for 10 minutes and pellet was resuspended in 200µl of TE before DNA extraction. 200µl of
- 140 pre-treated samples was subjected to an automated extraction on a MagNA Pure 96 nucleic
- 141 extraction system (Roche applied sciences, UK), according to the manufacturers
- 142 recommendations.

143 **Primer Design**

- 144 Twenty primer sets were designed based on the conserved regions which can produce
- 145 amplicons having melting temperatures (*Tm*s) ranging from 75°C to 92°C and target-specific *Tm*
- 146 values differed from each other by at least 1° C. The primer sequences and their optimal
- 147 concentrations are described in Table 1. The actual T_m of all primers was determined following
- 148 the performance of singleplex PCRs and multiplex PCRs.
- 149

150 For simultaneous detection of the six LRTIs pathogens, six primer pairs were designed targeting

- the known species-specific genes that have been published previously (*yaiO* for *E. coli* ¹⁷ 151 ; *ompA*
- for *A. baumannii* 18; *oatA* for *P. aeruginosa* 19; *sa442* for *S. aureus* 16; *ply* for *S. pneumoniae* ¹⁶ 152
- 153 and *khe* for *K. pneumoniae* ¹⁹. Additionally, fourteen primers were also designed to identify
- 154 fourteen common acquired AMR genes present in these bacteria, encoding resistance to β-
- 155 lactams (*bla*_{SHV}, *bla*_{TEM}, *bla*_{CTX-M-9}, *bla*_{CTX-M-1}), methicillin (*mecA*), carbapenems (*bla_{KPC}*, *bla*_{NDM},
- 156 *bla*_{OXA-48}, *bla*_{OXA-23}, *bla_{IMP}*), colistin (*mcr-1*), macrolides (*ermB, mphA*) and vancomycin (*vanA*).

157 **Development of EG-mPCR assays**

158 Singleplex real-time PCR assays were performed in 20μl reaction volume, which included 5μl 159 DNA template, 0.8μl forward and reverse primers and 10μl SensiFAST HRM kit (Meridian 160 Bioscience), to check the actual *Tm*s of each individual target amplicon. Sterile purified water 161 was used as the negative control. PCR amplifications were run on a LightCycler 480II (Roche 162 applied sciences, UK) with the following thermal conditions: initial denaturation at 95° C for 5min, 163 followed by 40 cycles of denaturation, 95°C, for 10 s; annealing, 60°C for 30 s; extension, 72°C 164 for 30s. For multiplex real-time PCR assays, the component and thermal condition were the 165 same as singleplex real-time PCRs, except the concentration of each primer pair varied from 166 0.25 μM to 0.5 μM. After PCR amplification, the melting curve analysis (MCA) was conducted in 167 the same thermocycler at 65°C to 95°C; and cooling cycle at 37°C for 30 s. Fluorescence was 168 continuously measured and the melting temperature (T_m) was calculated by plotting the 169 negative derivative of fluorescence over temperature versus temperature (−d*F*/d*T* versus *T*). 170 Conventional PCRs with a different set of primers were later performed to confirm the results of 171 EG-mPCR assays.

172 The reproducibility, linearity, limit of detection (LOD) of EG-mPCR assays for pathogen 173 detection were evaluated using 5-fold serial dilutions of two DNA control mixes. Each DNA 174 control mix was prepared by pooling equal volume of 10^8 CFU/mL of each bacterium, followed 175 by DNA extraction. Subsequently, 5-fold serially diluted DNA standards, corresponding to the 176 bacterial concentrations from 10^6 to 12.8 CFU/mL, were prepared for the assays.

177 To validate the assays in TA specimen, 200µl pre-treated culture-negative TA specimen was 178 spiked with 5-fold serial dilutions of bacteria (from 10^6 to 12.8 CFU/mL), followed by DNA

extraction using Roche's MagNA Pure 96 system. The EG-mPCR assays were performed as described above.

Diagnostic performance of EG-mPCR assays in comparison to conventional culture.

- Fifty TA and sputum samples were diagnosed using both the EG-mPCR assays and
- conventional microbiological culture and the results were compared between the two methods.
- The samples that were culture-negative but EG-mPCR positive were further confirmed by
- singleplex EG-PCR and conventional PCR. In addition, the correlation between the presence of
- AMR gene and AMR phenotype was also examined. The degree of agreement between EG-
- mPCR assays and conventional culture for bacterial identification was measured by Cohen's
- 188 kappa .

Ethic statement

- The study did not collect patient's information or require taking additional samples from patients.
- Informed consent is waved by the Institutional Ethical Review Committee of Hospital of Tropical
- Diseases in Ho Chi Minh city.

RESULTS

Detection of six bacteria and AMR genes by EG-mPCR assays

- Two EG-mPCR assays were used to detect 6 bacterial pathogens and additional three EG-
- mPCR assays were used to detect 14 AMR genes (Table 1). In each EG-mPCR assay, the
- melting curve analysis showed distinct Tm peaks corresponding to the target bacteria and AMR
- genes, while negative controls did not show any signal (Figure 1). The difference between two
- consecutive peaks was more than 2°C (Table 2). There was no interference and cross-reactivity
- in our EG-mPCR assays. We additionally evaluated our assays on other closely related bacteria
- and did not find any non-specific signal for *Salmonella* Typhi*, Campylobacter jejuni,*
- *Acinetobacter lwoffii, Staphylococcus epidermidis*. However, the *yaiO* primer which was
- supposed to be specific to *E. coli*, gave false positive signal for one *Shigella sonnei* isolate.

Reproducibility, quantification and LOD of the two EG-mPCR assays for bacterial

identification

The reproducibility of EG-mPCR assays was evaluated by accessing *Tm* values in inter and intra-assays. The standard deviation (SD) and coefficient variation (CV) of *Tm* were calculated in 5 replicates within the same run (intra-assay) and across 5 different runs (inter-assay). The intra-assay CV of each of the target bacteria ranged from 0.1% to 0.4% and the inter-assay CV ranged from 0.3% to 0.5%. Similarly, intra-assay CV and inter-assay CV of each of the target AMR genes varied from 0.04% to 0.57% and from 0.51% to 0.92%, respectively (Table 2). These data indicated good reproducibility of Tm values in our assays.

- The standard curve for each bacterium in the two EG-mPCR assays was obtained by plotting 214 the fluorescence intensity (−d*F*/d*T*) or the height of the peak (*y*-axis) values against the log₁₀ of the bacterial concentrations (*x*-axis) inferred from the serially diluted DNA control mixes. The 216 coefficient of determination of linear regression model of standard curves were R^2 =0.92 for *S.* 217 aureus, R^2 =0.92 for *S. pneumoniae,* R^2 =0.91 for *E. coli*, R^2 =0.97 for *A. baumannii*, R^2 =0.98 for $\,$ *K. pneumoniae* and R^2 =0.95 for *P. aeruginosa.* These data indicated a good linear correlation 219 between the fluorescence values and the $log₁₀$ of bacterial concentration over a range of bacterial concentrations.
- The limit of detection (LOD) was evaluated by observing the Tm peaks of each bacterium in the 222 two serially diluted DNA control mixes. The experiment was performed in 5 replicates within the same run and in 10 replicates between different runs. Based on the lowest concentration of a 224 target bacterium in a control mix where all targets showed positive signal, a LOD of 1600 CFU/mL was identified for each of the two EG-mPCR assays (Figure 2). When a TA specimen was spiked with target bacteria, a LOD of 3200 CFU/mL was identified for each of the two EG-mPCR assays.

Diagnostic performance of EG-mPCR assays in comparison to conventional culture

Between December 2020 and March 2021, 50 consecutive TA and sputum specimens were 230 included for both conventional culture and EG-mPCR assays. Conventional culture showed that

- 76% (38/50) of samples were culture positive for single target pathogen and 16% (8/50) were
- 232 culture positive for more than one pathogen (including 4 pathogens not covered in the PCR
- detection assays: *Haemophilus influenzae*, *Moraxella*, *Stenotrophomonas maltophilia*,
- *Enterobacter*). *P. aeruginosa* was the most prevalent pathogen (26%, 13/50), followed by *A.*
- *baumannii* (20%, 10/50), *S. aureus* (18%, 9/50), *K. pneumoniae* (12%, 6/50) and *E. coli* (2%,

1/50) (Table 4). Three samples (6%) were culture negative for all six pathogens. Overall, the microbiological culture from TA and sputum samples yielded a total of 51 target pathogens.

According EG-mPCR results, 56% (28/50) of samples had one peak with strong fluorescence signal and were identified as single infections. There were 18 samples (36%) showed at least 2 melting curve peaks with strong fluorescence signals, which were identified as co-infections. The most common patterns of co-infections detected by PCR were *P. aeruginosa* and *S. pneumoniae* (3/18) and *P. aeruginosa* and *S. aureus* (3/18), *P. aeruginosa* and *K. pneumoniae* (2/18) and *P. aeruginosa* and *A. baumannii* (2/18). *P. aeruginosa* (12/18) was the most common pathogen detected in co-infections (Figure 3). EG-mPCR showed negative results in 4 samples, three of which were also culture negative. Overall, EG-mPCR assays yielded a total of 67 target

pathogens.

Compared to conventional culture, the sensitivity and specificity of EG-mPCR assays for *K.*

pneumoniae, *A. baumannii*, *P. aeruginosa*, *E. coli*, *S. aureus* were 100% and 97.5%, 100% and

97.2%, 100% and 87.5%, 100% and 93.8%, 63.6% and 94.9%, respectively (Table 3). The

positive predictive value (PPV) and negative predictive value (NPV) of EG-mPCR assays were

90.9% and 100% for *K. pneumoniae*, 93.3% and 100% for *A. baumannii*, 81.8% and 100% for

P. aeruginosa, 50% and 100% for *E. coli* and 77.8% and 90.2% for *S. aureus*, respectively.

Out of the microbiologically-confirmed 51 target pathogens, 48 pathogens (94.1%) were also 254 detected by EG-mPCR assays with a quantitative result $\geq 10^5$ CFU/mL, which is a cut off of culture positivity (Figure 4A). Our data demonstrated a high degree of similarity between EG-mPCR assays and culture method. When considering only microbiologically-confirmed target 257 pathogens with growth $\geq 10^5$ CFU/mL (n=26) in TA samples, concordant PCR-based quantitative results were found in 100% (11/11) of *A. baumannii*, 100% (1/1) of *E. coli*, 100% (5/5) of *K. pneumoniae,* 100% (8/8) of *P. aeruginosa* and 100% (1/1) of *S. aureus* (Figure 4B)*.* There were however discordant results between the two methods. The culture method did not grow any *S. pneumoniae* isolates whereas the PCR assay found 6 *S. pneumoniae* with a 262 guantity ranging from $10^{3.6}$ to 10⁹ CFU/mL; furthermore, the culture failed to detect another 10 263 target bacteria that were identified by PCR (8 bacteria with a quantity ≥ 10⁵ CFU/mL and 2 264 bacteria with a quantity <10⁵ CFU/mL) (Figure 4A). Consequently, a total of 26 isolates were identified by PCR as mixed infections, for which only 11 isolates were identified by culture method as single infections and 15 isolates were missing from the culture results.

267 **Application of EG-mPCR assays for AMR gene detection from clinical samples**

268 Three EG-mPCR assays were used to identify 14 AMR genes commonly present in the target 269 pathogens from 50 clinical samples. After excluding mixed infections by PCR, the level of 270 correlation between the presence of AMR gene and AMR phenotype was assessed in 28 target 271 bacteria. The overall distribution of AMR genes and AMR profiles of 28 target bacteria are 272 shown in Table 4 and Figure 6. In *A. baumannii*, 100% (7/7) of the isolates carried *bla*_{OXA23} and 273 *bla_{TEM}* were resistant to ceftazidime, cefepime and carbapenem (imipenem, meropenem). 274 Among 4 *K. pneumoniae* isolates that were resistant to $3rd$ and $4th$ - generation cephalosporins 275 (ceftriaxone, cefotaxime, cefepime), $bla_{CTX-M-1}$ was found in all 4 isolates and bla_{TEM} was found in 276 3/4 isolates. *Bla*_{NDM} and *bla*_{OXA48} genes were both detected in two carbapenem resistant *K*. 277 *pneumoniae* isolates. For *P. aeruginosa, bla*_{OXA23} was found in one isolate that was resistant to 278 imipenem and meropenem and *bla*_{CTX-M-9} was found in another isolate that was resistant to the 3rd 279 generation cephalosporin (ceftriaxone, cefotaxime). Among five *S. aureus* isolates that were 280 resistant to macrolides (clindamycin), *emrB* gene was detected in 3 isolates (60%). Two isolates 281 (1 *K. pneumoniae* and 1 A*. baumannii*) were resistant to colistin, but no resistance genes were 282 found. There was one *E. coli* isolate resistant to cefotaxime and imipenem for which *bla*_{SHV} and

283 *bla*_{TEM} were identified but carbapenem resistance genes were undetected.

284 **DISCUSSION**

285 The selection and duration of effective empirical antibiotic treatment for LRTIs have become a major challenge in LMIC settings where MDR causative bacteria are prevalent. Although culture-guided definitive treatment is often followed to avoid overuse/misuse of initial antibiotics, the long waiting time for culture results has delayed effective antibiotic therapy, posing increased risks of mortality and selection of antimicrobial resistant organisms. Rapid and inexpensive molecular PCR-based diagnostics is urgently needed in clinical practice to inform antibiotic therapy. Here, we successfully developed two EG-mPCR assays to detect and quantify 6 major bacterial pathogens and three EG-mPCR assays to identify 14 AMR genes 293 directly from TA and sputum samples. The two PCR assays for pathogen detection exhibited high sensitivity (from 63.6% to 100%) and high specificity (from 87.5% to 97.5%) compared to conventional culture. The turnaround time from sample collection to the final PCR results was less than 6 hours.

A key advantage of our PCR assays is the ability to quantify the amount of each bacterium in a multiplex PCR reaction and thus could distinguish between bacterial colonization and infection. In fact, the quantitative data from the PCR assays demonstrated 100% concordance with quantitative microbiological culture results of TA samples. A previous study using a similar method raised concern about the reduced linear relationship between fluorescence levels and bacterial concentration in multiplex PCR assays, which may be attributed to the competition 303 amongst EvaGreen dyes 15 . This limitation has been addressed in this work by increasing the amount of the PCR mix and adding extra EvaGreen dye to the reaction. Our experiments 305 showed a good linear correlation (R^2 >0.91) between fluorescence readings and the log10 of 306 bacterial concentrations. Furthermore, the LOD of PCR assays (10 $^{3.6}$ CFU/mL) was much lower than the cut-off points for culture positivity ($\geq 10^5$ CFU/mL), meaning our assays not only could
308 identify true pathogens above the cut-off but also detect other potentially pathogenic bacteria identify true pathogens above the cut-off but also detect other potentially pathogenic bacteria present with lower concentrations for further monitoring.

Notably, PCR assays were able to detect more mixed target bacteria in the respiratory samples. The facts that EG-mPCR assays were more sensitive than conventional culture in detecting mixed infections, of which most target bacteria had a concentration $>10^5$ CFU/mL suggested that culture method may have missed some true target pathogens in the sample. Although conventional culture is considered as the gold standard for the diagnosis of bacterial LRTIs, it may be challenging to accurately recover all pathogens from a nonsterile sample. Alternatively, recent antibiotic treatment may affect the culture results and some target bacteria may present 317 at a concentration $<$ 10⁵ CFU/mL and thus not detected by culture method. Mixed bacteria by PCRs with quantitative results above the culture positivity cut-off can be regarded as a recent or current mixed infection. On the other hand, mixed bacteria by PCRs with quantitative result(s) below the cut-off should be followed up by additional PCR testing to confirm the pathogens.

In this study, *S. pneumoniae* were only found by PCR assays in mixed infections, which was the main factor affecting the agreement between the two methods. *S. pneumoniae* was notoriously difficult to identify by conventional culture because the bacteria tends to autolyze after reaching 325 the stationary phase, as well as the effect of prior antibiotic treatment . Previous studies comparing multiplex PCR with culture for the detection of *S. pneumoniae* and *H. influenzae* from 327 sputum also found similar results with *S. pneumoniae* only found by qPCR²². Our quantitative PCR assay therefore could serve as a useful diagnostic tool to detect *S. pneumoniae* from respiratory samples.

The use of EG-mPCR assays for AMR gene identification was also evaluated using 50 clinical samples. Overall, our findings demonstrated a high agreement between the detected AMR genes and the AMR profiles of target bacteria present in single infections. This means our assays can rapidly identify clinically relevant AMR genes to guide antibiotic therapy. As PCRs tend to detect more mixed infections, there may be some uncertainty about which AMR genes belong to which bacteria in these samples. However, the distribution of species-specific AMR genes in single infections and an understanding of local epidemiology of bacteria-drug resistance combinations can help to predict the most probable combinations of AMR gene-bacteria in mixed infections. Further research with increased sample size will provide more concrete data to discern AMR gene-bacteria combinations in mixed infections.

Our study has some limitations. The EG-mPCR assay had low sensitivity for the detection of *S. aureus, probably due to its resistance to chemical lysis during DNA extraction ²³. This could be* improved in future investigation by sample treatment with lysozyme and lysostaphin enzyme during DNA extraction. Here we only looked for commonly acquired AMR genes in the target bacteria, disregarding the resistance mechanisms driven by single point mutations or overexpression of efflux pump, and thus the absence of AMR genes may not always correlate with a lack of phenotype. Furthermore, as we only target 6 key pathogens, the PCR-negative samples may contain other pathogens that are not included in our PCR assays.

In conclusion, our multiplex realtime-PCR with EvaGreen dye MCA assays have been proven to be sensitive and quantitative for rapid detection of 6 key pathogens and 14 AMR genes directly from respiratory samples. Our assays provide culture-independent information regarding bacterial pathogens and pathogen abundance in samples as well as the genotypic AMR status of LRTIs cases. Our method can possibly distinguish colonization and infection, offering an important tool to promote the optimal use of antibiotics and to monitor the clinical and antibiotic treatment response in patients with LRITs. The PCR assays have strong potentials to be adopted in clinical practice due to its feasibility, low cost and fast turnaround time. The potential impact of our PCR assays on antibiotic therapy warrants a thorough investigation to promote its implementation in clinical practice.

Acknowledgments

- We would like to thank all members of the Molecular Epidemiology group at Oxford University
- Clinical Research Unit (OUCRU) in Vietnam and the Microbiology Laboratory at Hospital for
- Tropical Diseases for their support during the conduct of the study.
-

Financial Support

- Dr Pham Thanh Duy is funded by Wellcome International Training Fellowship (grant number:
- 222983/Z/21/Z). The funders had no role in study design, data collection and analysis, decision
- to publish, or preparation of the manuscript.
-

Conflicts of interest

- The authors declare no competing interests.
-

References

- 1. Troeger, C. *et al.* Estimates of the global, regional, and national morbidity, mortality, and
- aetiologies of lower respiratory infections in 195 countries, 1990–2016: a systematic
- analysis for the Global Burden of Disease Study 2016. *Lancet Infect. Dis.* **18**, 1191–1210
- (2018).
- 2. Troeger, C. *et al.* Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for
- the Global Burden of Disease Study 2015. *Lancet Infect. Dis.* **17**, 1133–1161 (2017).
- 3. Cilloniz, C., Martin-Loeches, I., Garcia-Vidal, C., Jose, A. S. & Torres, A. Microbial
- etiology of pneumonia: Epidemiology, diagnosis and resistance patterns. *Int. J. Mol. Sci.* **17**, (2016).
- 4. Wahl, B. *et al.* Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000–15. *Lancet Glob. Heal.* **6**, e744–e757 (2018).

- 5. Guitor, A. K. & Wright, G. D. Antimicrobial Resistance and Respiratory Infections. *Chest* **154**, 1202–1212 (2018).
- 6. Metlay, J. P. & Singer, D. E. Outcomes in lower respiratory tract infections and the impact of antimicrobial drug resistance. *Clin. Microbiol. Infect.* **8**, 1–11 (2002).
- 7. Iregui, M., Ward, S., Sherman, G., Fraser, V. J. & Kollef, M. H. Clinical importance of
- delays in the initiation of appropriate antibiotic treatment for ventilator-associated
- pneumonia. *Chest* (2002) doi:10.1378/chest.122.1.262.
- 8. Metlay, J. P. & Singer, D. E. Outcomes in lower respiratory tract infections and the impact
- of antimicrobial drug resistance. *Clin. Microbiol. Infect.* (2002) doi:10.1046/j.1469-
- 0691.8.s.2.4.x.
- 9. Calderaro, A. *et al.* Respiratory Tract Infections and Laboratory Diagnostic Methods: A
- Review with A Focus on Syndromic Panel-Based Assays. *Microorganisms* **10**, (2022).
- 10. Zhao, C. *et al.* Development of a TaqMan Array card to target 21 purulent meningitis-related pathogens. *BMC Infect. Dis.* **19**, 1–10 (2019).
- 11. Liu, J. *et al.* A laboratory-developed taqman array card for simultaneous detection of 19 enteropathogens. *J. Clin. Microbiol.* **51**, 472–480 (2013).
- 12. Murphy, C. N. *et al.* Multicenter evaluation of the BioFire FilmArray Pneumonia/
- Pneumonia plus panel for detection and quantification of agents of lower respiratory tract infection. *J. Clin. Microbiol.* **58**, 1–20 (2020).
- 13. Van Der Westhuyzen, M., Samodien, N., Brink, A. J. & Moodley, C. Utility of the
- BioFire® FilmArray® Pneumonia Panel plus assay for syndromic testing of lower
- respiratory tract infections in a low/middle-income setting . *JAC-Antimicrobial Resist.* **5**,
- 1–8 (2022).
- 14. Mao, F., Leung, W. Y. & Xin, X. Characterization of EvaGreen and the implication of its physicochemical properties for qPCR applications. *BMC Biotechnol.* **7**, 1–16 (2007).
- 15. Hu, L., Han, B., Tong, Q., Xiao, H. & Cao, D. Detection of Eight Respiratory Bacterial

- Pathogens Based on Multiplex Real-Time PCR with Fluorescence Melting Curve
- Analysis. *Can. J. Infect. Dis. Med. Microbiol.* **2020**, (2020).
- 16. Anbazhagan, D. *et al.* Development of conventional and real-time multiplex PCR assays
- for the detection of nosocomial pathogens. *Brazilian J. Microbiol.* **42**, 448–458 (2011).
- 17. Molina, F. *et al.* Improved detection of Escherichia coli and coliform bacteria by multiplex
- PCR. *BMC Biotechnol. 2015 151* **15**, 1–9 (2015).
- 18. McConnell, M. J. *et al.* Quantitative real-time PCR for detection of Acinetobacter
- baumannii colonization in the hospital environment. *J. Clin. Microbiol.* **50**, 1412–1414
- (2012).
- 19. Edwards, T. *et al.* Speciation of common Gram-negative pathogens using a highly

multiplexed high resolution melt curve assay. *Sci. Rep.* **8**, 8–15 (2018).

- 20. Watson, P. F. & Petrie, A. Method agreement analysis: A review of correct methodology. *Theriogenology* **73**, 1167–1179 (2010).
- 21. Musher, D. M. *et al.* Can an etiologic agent be identified in adults who are hospitalized for
- community-acquired pneumonia: Results of a one-year study. *J. Infect.* **67**, 11–18 (2013).
- 22. Edin, A. *et al.* Development and laboratory evaluation of a real-time PCR assay for
- detecting viruses and bacteria of relevance for community-acquired pneumonia. *J. Mol.*
- *Diagnostics* **17**, 315–324 (2015).
- 23. Chapaval, L., Moon, D. H., Gomes, J. E., Duarte, F. R. & Tsai, S. M. An alternative method for Staphylococcus aureus DNA isolation. *Arq. Bras. Med. Vet. e Zootec.* **60**, 299–306 (2008).
-
-
-
-

Figures and Tables:

Figure 1. Melting curve analysis showing the melting temperature peaks (Tm) of 14 AMR genes (A, B, C) and 6 bacterial pathogens (D, E) and negative control (NTC) in 5 multiplex PCRs.

 Figure 2. The sensitivity of simultaneous detection of *S. aureus*, *S. pneumoniae*, *E. coli* (A) and *A. baumannii, K. pneumoniae, P. aeruginosa* (B) with concentrations ranging 10⁶ to 12.8
444 CFU/ml. LOD of simultaneous detection of DNA of S. aureus. S. pneumoniae. E. coli was 1600 CFU/ml. LOD of simultaneous detection of DNA of *S. aureus*, *S. pneumoniae*, *E. coli* was 1600 CFU/ml and the same for *A. baumannii, K. pneumoniae, P. aeruginosa.*

- **Figure 3.** Heatmap of bacterial mixed infection pattern detected by the EG-mPCR method in the
	- clinical samples.

 Figure 4. The detection and quantity of 6 target bacteria by EG-mPCR assays in accordance 451 with culture results (culture-negative, culture-positive with one target bacterium, culture-positive 452 with at least two target bacteria)

with at least two target bacteria)

- 453
454 **Figure 5.** The distribution of predicted AMR genes in co-infections
- **Figure 6**. The antimicrobial susceptibility testing results of target bacteria.
- **Table 1.** Sequences, concentrations of primers used for singleplex and multiplex real-time PCR
- assays
- **Table 2**. Tm values of primers used for singleplex and multiplex real-time PCR assays
- **Table 3.** Performance of EG-mPCR assays compared with the conventional culture method
- **Table 4.** Distribution of AMR genes in single infections identified by PCR assays
-
-

Figure 1. Melting curve analysis showing the melting temperature peaks (Tm) of 14 AMR genes (A, B, C) and 6 bacterial pathogens (D, E) and negative control (NTC) in 5 multiplex PCRs.

Figure 2. The sensitivity of simultaneous detection of *S. aureus*, *S. pneumoniae*, *E. coli* (A) and A. baumannii, K. pneumoniae, P. aeruginosa (B) with concentrations ranging 10⁶ to 12.8 CFU/ml. LOD of simultaneous detection of DNA of *S. aureus*, *S. pneumoniae*, *E. coli* was 1600 CFU/ml and the same for *A. baumannii, K. pneumoniae, P. aeruginosa.*

475 476

477

A P.aeruginosa $\overline{3}$ $\overline{4}$ $\overline{4}$ $\overline{4}$ 13 S.pneumoniae \overline{c} $\sqrt{2}$ 6 $\overline{4}$ Number of sample $\mathbf 2$ $\overline{6}$ \overline{c} K.pneumonia $\overline{1}$ $\overline{4}$ 12.5 10.0 $7.5\,$ $5.0\,$ 2.5 \overline{c} \overline{c} A.baumannii 6 $\overline{4}$ 0.0 6 $\overline{3}$ S.aureus 1 $\mathbf{1}$ $\,$ 1 E.coli \overline{c} $\mathbf{1}$ 1 E.coli S.aureus K.pneumoniae S.pneumoniae A.baumannii P.aeruginosa

Figure 3. Heatmap of bacterial mixed infection pattern detected by the EG-mPCR method in the clinical samples

Figure 4. The detection and quantity of 6 target bacteria by EG-mPCR assays in accordance with culture results (culture-negative, culture-positive with one target bacterium, culture-positive with at least two target bacteria)

Figure 5. The distribution of predicted AMR genes in co-infections

479 480

481 482

Figure 6. The antimicrobial susceptibility testing results of target bacteria

- 483
- 484
- 485

486 **Tables**

487 **Table 1.** Sequences, concentrations of primers used for singleplex and multiplex real-time PCR

488 assays

514 **Table 2**. Tm values of primers used for singleplex and multiplex real-time PCR assays

541 **Table 3.** Performance of EG-mPCR assays compared with the conventional culture method

Bacterial pathogens	EG- mPCR	Conventional culture method		Sensitivity	Specificity	PPV (%)	Kappa
		positive	negative	(%)	$(\%)$	$NPV(\%)$	
K. pneumoniae	positive	10		100	97.50	90.9	0.94
	negative	0	39			100	
A. baumannii	positive	14	1	100	97.22	93.3	0.95
	negative	0	35			100	
P. aeruginosa	positive	18	4	100	87.50	81.8	0.8
	negative	0	28			100	
E. coli	positive	$\overline{2}$	2	100	95.83	50	0.65
	negative	0	46			100	
S. aureus	positive	7	2	63.64	94.87	77.8	0.63
	negative	4	37			90.2	

⁵⁴²

543 **Table 4.** Distribution of AMR genes in single infections identified by PCR assays

544

546

547

548

- 549
- 550
-
- 551

552